Isotocyanozene

Last updated

Isotocyanozene
Isotocyanazene structure.png
Identifiers
  • 1-[2-(diethylamino)ethyl]-2-[(4-prop-2-yloxyphenyl)methyl]benzimidazole-5-carbonitrile
Chemical and physical data
Formula C24H30N4O
Molar mass 390.531 g·mol−1
3D model (JSmol)
  • CC(C)Oc1ccc(cc1)Cc1nc2cc(ccc2n1CCN(CC)CC)C#N

Isotocyanozene (5-cyano-isotodesnitazene) is a benzimidazole opioid analogue of isotonitazene which has been sold as a designer drug. It was first prospectively observed in a toxicological sample in the Scotland, United Kingdom in 2025, and was presumed to have opioid effects. [1] It has been identified by the drug checking service CanTEST, Australia in September 2025 as an expected 'opioid' sample, and then later as an expected 'benzodiazepine' sample. [2] [3] The relative activity of this benzimidazole opioid 'desnitazene' analogue is unknown.

See also

References

  1. ↑ McHenry RD, Dunlop LC, Hudson S, Walters M, Dear JW, Lowe DJ (July 2025). "Isotocyanozene: detection of the 5-cyano analog of isotonitazene in human biological samples". Clinical Toxicology. 63 (9). Philadelphia, Pa.: 691–692. doi:10.1080/15563650.2025.2528990. PMID   40625206.
  2. ↑ CanTEST Health and drug checking service, Canberra (September 2025). "Community Notice 22nd of September 2025: Isotocyanozene found in 'opioid' capsule". Instagram, official account of CanTEST.{{cite web}}: CS1 maint: multiple names: authors list (link)
  3. ↑ "Isotocyanozene found in 'opioid' capsule - The Know". 2025-09-22. Retrieved 2025-09-23.



This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.